Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tenor- I will try to answer your concerns. First, looking at the USPTO, there was lag time there due to the SAWS program. Many game changing, paradigm changing patents were slogged down by SAWS. It is not hard to assume that the ELTP bead patent could be one of those. PFE does have a lot of clout with the FDA and the FDA can be easily bribed. PFE actually got the FDA in trouble with Embeda so the FDA could not go forward without getting Embeda fixed and first to market. If the FDA approved ELTP prior to that they would have taken even more criticism because ELTP is so much better anyway. Getting Embeda going(for what it is worth, not much) was face saving for the FDA. For many reasons Embeda needed to be first to market. THen came Zohydro-another FDA mess. BUt the FDA got off the hook there when it was sold because it was not profitable to be produced and really not abuse resistant at all. Egalet got set back to the end of the year and made need further studies. Collegium will have manufactoring problems and distribution problems.Actually, they both will. Both will have to buy there Naltrexone from ELTP or the other company(I forget). So actually, considering the incompetence of the FDA and their bribes we are ahead of the pack. Our ace in the hole is NH with whom the FDA is very familiar. He has a lot of credibility, knows the ins and outs with the FDA, and soon will have them cornered to the point that the only thing they can say is "full speed ahead". I think Camargo may ask NH for some extra "research" money and NH will know what that means and the doors will fly open. The FDA does not have to wait 6 months to make a decision and I think they will not due to political pressure. The key on the OTC is patience.
Tenor-It is not exactly true that if the FDA is late with guidance or comments that we would be thrown off the schedule entirely. There is a lot of flexibility from Jul1-Dec30 in that the FDA does not have to use all 6 months to make a decision. It is in their(FDA) best interest to make a decision sooner.
Nas- Not only that but they cannot make their own naltrexone and they do not have as good of manufactoring facilities or distribution.
AJ-OOPS!. Sorry. I somehow missed that. I need more coffee. Well, at least we agree on $3.50 being most likely evaluation. Thanks again.
AJ - Thanks for the graph. If you have got your calculator still handy and hot from all those figures would you mind putting an additional evaluation at $3.50 or even better your own guess in your spreadsheet. Thanks so much for all you do for ELTP. Much appreciated.
I think $2.75 is too low considering the progress that has been made with the R&D and USPTO since that evaluation was done. But, in addition, looking at real dollars and including the launching of isradipine I am thinking in the neighborhood of $3.50. After all our Q results have gone up quarter after quarter for years now from the time of that evaluation.
n2k- I agree with your comments on shorting. It indeed has gone down below 20% from as high as 40%. To me this means a stable SP and accounts for the gradual creeping up in price. MMs are resigned now to the fact that the hand writing is on the wall. You can fight progress for only so long. Everyone on this board really knows who knows what is going on vrs. just a barrage of misinformation. TIme is on our side and as each day goes we are closer to our goal.
Couch- You are correct in that ELTP can treat drug addiction (narcotics,alcohol). ELTP can make Naltrexone. This drug is used to treat drug addiction (Int J High Risk Behav Addict. 2014. Sep. 17(4):3., a free article on Pubmed), Multiple sclerosis, Crohns, fibromyalgia, chronic fatigue, obesity(great for weight loss), and even cancer. Naltrexone in and of itself is a gold mine drug and is as valuable as ELI200 and its sisters. NH needs to get this drug to the market as soon as possible. As you already know drug addiction occurs on the microglia. It is the dysregulation of microglia that is treated. If NH and ELTP can make Naltrexone they can make Naloxone. NH has the brain power to make Naloxone. This drug as you know can save patients from drug overdose. The price for Naltrexone and Naloxone has sky rocketed very recently. ELTP would be a major success (billions) on just being able to make Naloxone and Naltrexone alone. The gold mine generic is Naltrexone and will increase the SP in a major way just on its own.
Nas- I could not agree more. It comes down to the size of the bead and the universal and interchangeable manufactoring capabilities for many different drugs not just ELI20 or ART. Our process is far less expensive, we have spent far less in research and development and with our increased production capacity we will be able to get drugs to market much faster. I do not know if you noticed but the cost of Naltrexone and Naloxone has sky rocked lately. Gee- I think ELTP can make that drug.
Zogenix giving up on Zyhydro is great news for ELTP. This was another big issue facing the FDA and the FDA took a lot of criticism over their decision for the go ahead in this drug. Now they do not have to deal with this headache any more. ELTP has moved up a notch on the FDA to-do list. With Embeda basically done, the FDA can focus on ELTP which will finally bail out the FDA from any more criticism. I believe things will speed up for ELTP.
Gman- I think we finally start up for good in July when we submit to FDA the test results from the study starting soon. I know it takes 8 weeks to collect the data but this will be the fastest study Camargo has ever done.The study will be finished the next day after collecting the data. They will probably have it pre-written and just plug in numbers and off it goes to the FDA. We already know the results. It would also help if our patent is approved as well. I am sure the FDA will feel better after the Embeda debacle which I think has made it harder for everyone who followed PFE in ART.
Gman- Just a little patience. We will all be okay!
Couch- Good thought and this may be a prearranged premium above the daily average or close. Thanks for the warning by the way. I will be more careful.
Couch- Good thought and this may be a prearranged premium above the daily average or close. Thanks for the warning by the way. I will be more careful.
julesnemo3- Thanks for your DD. Much appreciated.
Rd-It should say so in the announcement but he could have been exercising warrants. But again, that is usually stated. I do not think ELTP hit .342 on 5 March. He could also have made a deal with one of the MMs to buy those shares at that price. They could have been after the market evening purchases.
I do not think it was a error. NH bought those shares apparently as soon as he had the funds to do so. This means something good is happening very soon. I think there is a time limit ahead of time before a PR in which he can buy shares and just wanted more shares before he makes an announcement. He cant buy shares the day before, make an announcement, and sell the day after. It seems after the announcement .342 will be cheap. THis is very positive.
Lasers-Thanks for the DD. How much better can this get. It speaks volumes for NH's confidence in ELTP, in the FDA and research results, and in a buyout or partner. This is the best buy signal you can have. I am buying while I can.It also says something good is happening in the near future.
Considering that big pharmas especially PFE have not invested heavily in R and D but rely on buying out companies with new technology, PFE a has made a big mistake. They bought a patent for a hugh amount of money that NH already knew would not work. Rather than admit failure and that they messed up they spent years and millions investing in trying to make this work. This turned out to be disastrous for PFE considering any other big pharma can come along and buyout ELTP and pay a good price for ELTP and still not only save R and D expenses but add significantly to their bottom line plus have the option of expanding this technology to other meds they have. Oops CEO of PFE made a high mistake that will cost him his job.
Turtle shell technology is dead from the point of view of difficulty and expense to produce. Plus it is less effective as a medication. The smaller the head the better the medication. Turtle shell technology does not have the flexibility that microbead technology has to be used in many different medications. Seriously, the CEO of PFE is in trouble and may lose his job over this. PFE a could have bought ELTP for a great price for 10x less than they spent trying to develop an outdated inflexible less efficient technology.
Jtf3- That is funny considering PFE went through many years of failures with Embeda and has exhausted a huge amount of time on the patent just to be able MAYBE to get it to work. It will never ever be as good as Eli200 and is based on outdated turtle shell technology which will be short lived on the market.
Nobody wants to copy Embeda anyway. It is an inferior product.
If there is any patent that is running out of time it is the turtle shell patent for Embeda but it is worthless anyway and not worth what was paid for it anyway. They paid for a patent that did not work, spent millions trying to make It work, and it will be on the market only a short while before ELI200 will undercut the price which will be easy because of the far less development process and be far superior as tests already show. This will cost the CEO his job at pFE
Gman-hope you are having a nice day. The patent is important because otherwise Embeda would be patent protected and we would fall under generic status. By having our own separate patented manufacturing process we become our own drug and are not subject to generic status which would block our manyfactoring anything.
Dr l - wrong again! FDA has already commented they had never seen a process like this before. I am sure having a patent for this process would be important to the FDA.
When the micro capsule patent is approved then this will speed things up with the FDA. With the SAWS program gone now hopefully this will speed things up even more.
When they are tracking the 5th decimal point over on the SP they are in trouble. Notice they are trying very hard not to round up. Keep up the buying, holding, and accumulating.
Dr.L. -How can it be an also ran patent if it is concluded by the USPTO that it can be patented.
Couch- I could not agree more. NH is a pro. He has great respect at the FDA. He has a great history in big pharma which is why so many of his previous coworkers quit their jobs to follow him. Thanks for all the contributions you make to ELTP if I have not expressed my thanks to you before.
Clarenden-It does not matter if the patents are due in 2024. There will be child patents as usual which will extend the life of the patents. The patent life can be extended as well by the USPTO. Finally, ELTP will be bought out before 2024. You and Money tree will profit nicely on ELTP just like everyone else well before 2024.
Dr. L. I am shocked and totally beside myself that you of all people would actually request "links". I am not referring to experts but to test results which we have been around and around with for weeks now. These links have been posted for a long time now by many people.
I feel the SAWS program, which stalled patent applications, was an effort to regulate the economy and protect jobs and big corporations by slowing down innovation. Remember the 100 miles per gallon carburetor of many years ago that just went missing.It went missing to protect the economy and jobs and major oil corporations. Ending this program, essentially there to protect big corporations like big pharma , speeds up patent applications and protects small companies like ELTP. It is also a signal to the FDA that that things are going to be moving faster. The FDA is, in my point of view, politely delaying ELTP until PFE is first to market and Zyhydro is squared away to avoid further criticism. Then comes ELTP's turn. Essentially PFE got a one year headstart (or I hope less now) out of the deal. But I think this is the last favor PFE gets from the FDA on ART. I think putting ELTP first in line would have brought further criticism to the FDA and brought closer scrutiny of the FDA in that they would look even more stupid for playing around with PFE. Everyone knows ELTP patents are superior in every way and ELI200 is superior to Embeda. And we have gained a lot of advantages by not being first on the block and paving unknown territory.We will definitely have the pricing advantage as well. But there were many lives lost by the careless attitude of the FDA and their bribes.
Additional help for ELTP-The government just eliminated their SAWS program.This was a secret program to delay patent applications. This will indirectly help us move through the FDA quicker.
The downturn will reduce the kiss of death and be profitable for those not subject to the kiss of death.
I agree.The downturn will also result in less deaths
I think the most important date is 1July, 2015. With successful test results, the weakening of required tests for PFE and Zyhydro, plus policitcal pressure on the FDA we will not be waiting 6 months. The SP will really start going up at that time. From that point it is a matter of dotting i's and crossing t's. It will all be down hill from there.
The one thing we can be sure of is that time is on our side. We will not see the teens again.
Off to Avery nice start this AM.
Once ELTP is bought out I would try to be invested in the company that buys out ELTP for a double header winner. Which ever big pharma takes over ELTP technology will be a big winner. I am sure NH will be given a position in this company as well. I am sure with millions of shares he could retire but he is too ambitious to quit after ELTP is bought out.
Which company on the NYSE or NASDAQ is the only company to have increasing revenues for 8 or 9 quarters ( I believe that number is correct, might be more) in a row under these recent tough economic conditions? ELTP!